Drugs / Exl-111
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07356713 | Jan → Dec 2026 expected | allergic disease | Excellergy Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exl-111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07356713 ↗ |
| Route | Subcutaneous | “Exl-111 is administered by subcutaneous injection in a single dose.” NCT07356713 ↗ |